Expression of cell-cycle-regulated proteins prb2/p130, p107, p27kip1, p53, mdm-2, and ki-67 (mib-1) in prostatic gland adenocarcinoma

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 1808-1815

  Claudio, Pier Paolo ^a,b,c   Zamparelli, Alessandra ^a,b   Garcia, Fernando U ^d   Claudio, Luigi ^e   Ammirati, Giuseppe ^f   Farina, Antonio ^g   Bovicelli, Alessandro ^a,b   Russo, Giuseppe ^a,b   Giordano, Giovan Giacomo ^h   McGinnis, David E ^b   Giordano, Antonio ^a,b   Cardi, Gaetano ⁱ  

^a TEMPLE UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P107; PROTEIN P130; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADENOCARCINOMA; ADULT; AGED; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036285205     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Cancer statistics
2. Chemotherapy in advanced prostate cancer
3. The p53 tumour suppressor gene
4. Clinical implications of the p53 tumor-suppressor gene
5. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
6. p53 expression and prognosis in gastric carcinoma
7. Prostatic carcinoma: A multivariate analysis of prognostic factors
8. Immuno-histochemical detection of p53 protein as a prognostic indicator in prostate cancer
9. p53 oncogene mutations in human prostate cancer specimens
10. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
11. p53 is mutated in a subset of advanced-stage prostate cancers
12. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
13. p53 in prostate cancer: Frequent expressed transition mutations
14. Functions of the MDM2 oncoprotein
15. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas
16. 1 restriction point
17. la.B) invasive breast carcinomas
18. Decreased levels of the cell-cycle inhibitor p27Kipl protein: Prognostic implications in primary breast cancer
19. Expression of cell-cycle regulators p27Kipl and cyclin E. Alone and in combination, correlate with survival in young breast cancer patients
20. p27 expression and gastric carcinoma
21. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
22. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
23. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
24. Loss of cyclin-dependent kinase inhibitor p27Kipl is a novel prognostic factor in localized human prostate adenocarcinoma
25. Expression of p27kipl in prostatic adenocarcinoma
26. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
27. Association of p27Kipl levels with recurrence and survival in patients with stage C prostate carcinoma
28. Distinct altered patterns of p27KIPI gene expression in benign prostatic hyperplasia and prostatic carcinoma
29. Consensus review of the clinical utility of DNA content cytometry in prostate cancer
30. Bcl-2 oncoprotein positivity and high MIB-l (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
31. The RB family of cell cycle regulatory factors
32. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107
33. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein
34. The retino-blastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19
35. Loss of the retinoblastoma protein-related p 130 protein in small cell lung carcinoma
36. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer
37. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer
38. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer
39. Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma
40. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors
41. Expression of the retinoblastoma-related gene Rb2/130 correlates with clinical outcome in endometrial cancer
42. Differential expression of the retinoblastoma gene family members in choroidal melanoma: Prognostic significance
43. Histologic grading and clinical staging of carcinoma of the prostate
44. The expression of waf-l, p53 and bcl-2 in prostatic adenocarcinoma
45. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors
46. Loss of the cyclin-dependent kinase inhibitor p27(Kipl) protein in human prostate cancer correlates with tumor grade
47. Levels of expression of p27KIPI protein in human prostate and prostate cancer: An immunohistochemical analysis
48. Predictive value of decreased p27Kipl protein expression for the recurrence-free and long-term survival of prostate cancer patients
49. The multidisciplinary clinic approach to prostate cancer counseling and treatment
50. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
51. Loss of the retinoblastoma susceptibility gene (RBI) is a frequent and early event in prostatic tumorigenesis
52. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies
53. Tumor suppressor genes in prostatic oncogenesis
54. Immuno-histochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate
55. The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies
56. Retinoblastoma-related gene Rb2/p13O expression in normal, hyperplastic and malignant endometrium
57. Expression of cell-cycle-associated proteins pRB2/p130 and p27/Kipl in vulvar squamous cell carcinomas
58. Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy